Outcomes After Salvage Radiation Therapy for Recurrent Endometrial Cancer in Patients With No Prior Adjuvant Therapy: An Institutional Review.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Historique:
received: 28 04 2020
revised: 25 08 2020
accepted: 28 08 2020
entrez: 11 12 2020
pubmed: 12 12 2020
medline: 12 12 2020
Statut: epublish

Résumé

After definitive surgery, women with early-stage, low-risk endometrial cancer are observed. However, some will require salvage radiation therapy for recurrence. The purpose of this study was to evaluate our experience using salvage radiation for recurrent endometrial cancer in patients who did not receive upfront adjuvant therapy. Twenty-eight women with endometrial cancer who had undergone initial definitive hysterectomy without adjuvant therapy developed isolated local or regional recurrence and were treated with salvage radiation in our department from 2004 to 2018. Salvage radiation included whole pelvic radiation, vaginal brachytherapy, or both. Patient and tumor characteristics, treatment details, and toxicities were recorded and analyzed. The median time to first recurrence was 1.7 years. First recurrences consisted of local recurrence in 23 patients, regional recurrence in 4, and both in 1. The median times from hysterectomy to first recurrence, local and regional, were 1.2 and 4.0 years, respectively. All patients underwent salvage radiation for management of their first recurrence. The median total equivalent dose in 2 Gy fractions for this treatment was 67.6 Gy (37.5-81.8 Gy). Two second recurrences occurred following salvage treatment, both local recurrence, at 6.5 and 13.5 months after radiation. The 2-year rates of local control, disease-free survival, and overall survival were 93%, 80%, and 88%, respectively. Treatment was well-tolerated, with low rates of gastrointestinal and genitourinary toxicity. In this group of patients, salvage radiation therapy for local or regional recurrence of endometrial cancer resulted in excellent control with low rates of acute and chronic toxicities.

Identifiants

pubmed: 33305085
doi: 10.1016/j.adro.2020.08.012
pii: S2452-1094(20)30223-2
pmc: PMC7718518
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1240-1247

Informations de copyright

© 2020 The Authors.

Références

Int J Gynecol Cancer. 2009 Jul;19(5):873-8
pubmed: 19574776
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):500-4
pubmed: 16168841
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8
pubmed: 21640520
Gynecol Oncol. 2004 Mar;92(3):744-51
pubmed: 14984936
Radiother Oncol. 2002 Oct;65(1):23-8
pubmed: 12413671
Gynecol Oncol. 2006 Jun;101(3):520-9
pubmed: 16556457
Clin Radiol. 2007 Jan;62(1):28-34; discussion 35-6
pubmed: 17145260
Lancet. 2000 Apr 22;355(9213):1404-11
pubmed: 10791524
Am J Obstet Gynecol. 2011 Jun;204(6):466-78
pubmed: 21752752
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43
pubmed: 17161155
Gynecol Oncol. 1997 Jul;66(1):16-9
pubmed: 9234914
Pract Radiat Oncol. 2013 Jan-Mar;3(1):e21-e28
pubmed: 24674269
Cancer. 1994 Aug 15;74(4):1303-8
pubmed: 8055452
Radiother Oncol. 2014 Oct;113(1):126-31
pubmed: 25241996
J Contemp Brachytherapy. 2017 Jun;9(3):209-215
pubmed: 28725243
Gynecol Oncol. 2003 May;89(2):201-9
pubmed: 12713981
Cancer. 2003 May 15;97(10):2432-9
pubmed: 12733142
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1366-72
pubmed: 12873682
Brachytherapy. 2016 Nov - Dec;15(6):812-816
pubmed: 27614661
Gynecol Oncol. 2006 Jun;101(3):445-9
pubmed: 16386785
J Clin Oncol. 2009 Jul 20;27(21):3547-56
pubmed: 19546404
Int J Gynecol Cancer. 2007 Jul-Aug;17(4):886-9
pubmed: 17309665
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):405-13
pubmed: 10974454

Auteurs

Jessica D Arden (JD)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Morgan F Gruner (MF)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.
Ob/Gyn and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio.

Charles C Vu (CC)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.
Department of Radiation Oncology, Parkview Cancer Institute, Fort Wayne, Indiana.

Kimberly Marvin (K)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Hong Ye (H)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Sirisha R Nandalur (SR)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Zaid Al-Wahab (Z)

Department of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan.

Jill Gadzinski (J)

Department of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan.

Joseph Anthony Rakowski (JA)

Department of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan.

Jayson Field (J)

Department of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan.

Barry Rosen (B)

Department of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan.

Maha Saada Jawad (MS)

Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan.

Classifications MeSH